Immunity and inflammation play critical roles in the pathogenesis of acute ischemic stroke. Therefore, immune intervention, as a new therapeutic strategy, is worthy of exploration. Here, investigators tested the inflammation modulator, vinpocetine, for its effect on the outcomes of stroke. For this multi-center study, investigators recruited 60 patients with anterior cerebral circulation occlusion and onset of stroke that had exceeded 4.5 hours but lasted less than 48 hours. These patients, after randomly division into two groups, received either standard management alone (controls) or standard management plus vinpocetine (30 mg per day intravenously for 14 consecutive days, Gedeon Richter Plc., Hungary).
- Vinpocetine (Cavinton)Drug
Other Names: Cavinton Intervention Desc: 30 mg of the drug by intravenous infusion once daily, for fourteen consecutive days, beginning within one hour after the baseline MRI and no later than 48 hours after the onset of symptoms. ARM 1: Kind: Experimental Label: vinpocetine group Description: Aspirin, 10mg, po and 30 mg of the vinpocetine by intravenous infusion once daily, for fourteen consecutive days
- Aspirin Drug
Intervention Desc: 100mg, once daily, oral medication ARM 1: Kind: Experimental Label: vinpocetine group Description: Aspirin, 10mg, po and 30 mg of the vinpocetine by intravenous infusion once daily, for fourteen consecutive days ARM 2: Kind: Experimental Label: Control group Description: Patients will receive aspirin only.
- Allocation: Randomized
- Masking: Single Blind (Outcomes Assessor)
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
|Type||Measure||Time Frame||Safety Issue|
|Primary||changes in lesion volume||lesion volume from baseline to day 7||Yes|
|Primary||brain inflammatory level||day 7||Yes|
|Primary||extent of clinical improvement||from baseline to day 7 and 14||No|
|Secondary||probability of excellent recovery||at day 90||No|
|Secondary||cytotoxic edema||day 3||No|